4.5% – Decline in 2024 EBITDA estimates for publicly traded cannabis companies
With the rescheduling of cannabis still on the horizon, analysts with Viridian Capital Advisors expected EBITDA forecasts to rise as 2024 unfolded. But according to new analysis of 16 publicly traded cannabis companies, that expectation is far from reality. In aggregate, the group 2024 EBITDA estimates have been revised downward by 4.5% year-to-date, with 2.7% happening since the end of the second quarter.
Source: Viridian Capital Advisors
The post Number of the Week: 4.5% appeared first on Green Market Report.